Current Research Studies

SC-2046: A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of asciminib in pediatric participants newly diagnosed or previously treated with Philadelphia positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) with or without known T315I mutation

SC-2046

  • Condition(s): Leukemia, other, Myeloid and Monocytic Leukemia
  • Phase: II
  • Clinicaltrials.gov ID: NCT07354074

What is the goal of the study?

The aim of this study is to assess the efficacy and safety of asciminib in the Ph+ CML-CP pediatric participants (1 to < 18 years of age), newly diagnosed or previously treated with TKI with or without known T315I mutation.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team: